Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study

Ad hoc announcement pursuant to Art. 53 LRU.S. clinical hold remains in place; study continues in all other countriesCompany initiates expansion of clinical sites and enrollment in Europe, Asia and Latin AmericaTopline data from ENIGMA-TRS 1 expected in Q1 2027MILAN and MORRISTOWN, N.J., Sept. 25…